Cancer remains a major cause of human mortality. The greatest barrier to cure is resistance to conventional medical treatments. Therapy resistance arises through clonal evolution driven by genomic instability, fostered by selection as therapy-sensitive cells are eradicated. Such resistance has been attributed to alterations in numerous cellular pathways, yet many ultimately impact the process of mitochondrial apoptosis. The critical gatekeepers for mitochondrial apoptosis initiation are the Bcl2-homology (BH) proteins, whose interactions integrate the varied stressors a cell encounters and provide a live-or-die decision (reviewed in [1] ). As such, BH proteins are the frequent target of alterations in cancer cells during oncogenesis and tumor progression [2] .
Diverse cell stressors, chemotherapy and radiotherapy among them, activate downstream death signaling proteins within the BH3-only family (named for their inclusion of a specific BH death domain). Once activated, these BH3-only proteins (such as Bid, Bim, and Noxa) are free to interact with multi-domain BH proteins that reside at the outer mitochondrial membrane. Mitochondrial apoptosis requires a BH3-only protein to activate pro-apoptotic Bak or Bax, leading to their homo-oligomerization and release of apoptogenic factors from the mitochondria. This is a "point of no return" for a cell as it leads to terminal caspase activation as well as bioener- getic collapse ( Figure 1 ). An alternative outcome for an activated BH3-only protein is to be neutralized by a pro-survival BH protein. These family members (including Bcl2, BclX L , Bclw, Mcl1, BclB and A1/Bfl1) sequester BH3-only proteins and prevent them from engaging Bak/Bax. Differences in amino acid composition within their respective BH domains define their specificity of binding partners, and much of this has been worked out experimentally [3] . It is these interactions among the BH proteins, dictated by their stoichiometry and relative affinities, which are a critical determinant of apoptosis sensitivity for a cell.
Intuitively one recognizes that a cell with excess pro-survival BH proteins (such as Bcl2) will have a survival advantage. Perhaps less intuitively, this state may also render a cancer cell particularly vulnerable to additional stressors. Not all BH3-only proteins are equally capable of triggering Bak/ Bax activation, but Bim and Bid are uniquely adept. Cancer cells encountering stressors that activate Bid or Bim may survive if sufficient Bcl2 proteins are available to neutralize them. However, this state whereby activated Bid or Bim is bound to Bcl2 primes the cells such that an additional BH3-only signal (e.g., one activated by chemotherapy) can displace them leading to cell death. Indeed, this can be experimentally demonstrated [3, 4] .
An appreciation of these pathways has led to the development of therapeutics termed BH3 mimetics (or Bcl2 antagonists; reviewed in [5] ). These small molecules antagonize pro-survival BH proteins by competitively binding within their hydrophobic pocket. They tip the balance in BH3-only signal transduction toward the activation of Bak/ Bax, rather than sequestration within Bcl2. Pre-clinical models have shown activity for this therapeutic class for cancer, and a drug from Abbott, ABT-263, is now advancing through clinical trials. ABT-263 (and its parenteral relative, ABT-737) are potent antagonists of Bcl2, BclX L and Bclw, but have little affinity for the remaining family members, including Mcl1 [6] . This inability to antagonize Mcl1 is ABT-263's Achilles' Heel as Mcl1 expression correlates with resistance to this drug [7] .
Unfortunately, none of the BH3 mimetics under development are potent Mcl1 antagonists. Indeed, many "panBcl2 inhibitors" suffer from a lack of specificity (e.g., they are capable of killing cells that are Bax/Bak or Caspase 9 null), or are simply too weak to compete with native high-affinity BH3-only proteins for pro-survival BH pockets. It is for these reasons that the report by Schwickart et al. is so welcome [8] , as it may provide an alternative target for Mcl1 antagonism. Mcl1's own Achilles' Heel may lie in its tight regulation and extremely short half-life. Mcl1's protein structure is unique among BH proteins for its extended amino-terminus and inclusion of two PEST domains characteristic of short-lived proteins. Posttranslational modification (PTM) via phosphorylation downstream of varied signaling pathways, further regulates its stability and activity, as does the ubiquitin-proteasome pathway [9] .
Mcl1 is targeted for proteasomemediated degradation by the Hect E3-ligase HUWE1 (also called Mule, LASU1, ARF-BP1), accounting for its rapid turnover at steady state [10] . This E3-ligase is impeded when Mcl1 is bound to BH3-only proteins as they share carboxy-terminus binding regions and BH3-only proteins have higher affinity. An additional E3-ligase, β-TrCP (BTRC), operates in a phospho-dependent manner (P-Ser159) downstream of GSK3β to also destabilize Mcl1 [11] . Augmenting either pathway can reduce Mcl1 levels, however, pharmacologically activating physiologic functions is more difficult than inhibiting them. To date, no Mcl1 reduction strategy has capitalized on promoting Mcl1 ubiquitination. Schwickart et al. have taken an alternative approach focusing on the other half of the equation (Figure  1, box) .
Ubiquitin modification is reversible, with nearly 100 cysteine protease deubiquitinating enzymes (DUBs) identified [12] . The authors used a Flag-tagged Mcl1 and co-immunoprecipitated proteins in a DUB search that yielded USP9X. Though DUBs have been demonstrated to antagonize specific oncogenic and tumor suppressive E3-ligases and are viewed as emerging targets for cancer therapeutics [12] . To this list is added USP9X for its role in deubiquitinating and stabilizing Mcl1, a bona fide oncogene. The biochemical evidence for this activity is clear, but whether a therapeutic advantage is gained will require further efforts. Clearly, the Mcl1 knock-down achieved with genetic silencing is suboptimal, and even with sensitization to ABT-737, the concentration required for cytotoxicity is exceedingly high (IC50s >10 μM). In contrast, the most ABT-737 sensitive cells lacking Mcl1 have nearly 3-log greater sensitivity in vitro and tumor regression (rather than inhibition) can be demonstrated in vivo [6, 13] . The finding does, however, provide a rational strategy for high throughput screening approaches to identify small molecules that inhibit Usp9x-Mcl1 interaction, with a goal of potentiating Mcl1 antagonism further.
